Esperion Therapeutics

Yahoo Finance • 4 days ago

Biggest stock movers Wednesday: JOBY, IREN, and more

[Strategy stock chart financial graph analysis market exchange on growth business technology background with money diagram trade investment or digital progress candlestick finance data global success.] Lemon_tm Stock futures edged higher... Full story

Yahoo Finance • 5 days ago

Esperion Announces Pricing of Public Offering of Common Stock

ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-st... Full story

Yahoo Finance • 5 days ago

Esperion launches proposed public offering of common stock

* Esperion Therapeutics (NASDAQ:ESPR [https://seekingalpha.com/symbol/ESPR]) has commenced an underwritten public offering of shares of its common stock. Esperion also intends to grant the underwriters a 30-day option to purchase up to a... Full story

Yahoo Finance • 5 days ago

Esperion Announces Proposed Public Offering of Common Stock

ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-st... Full story

Yahoo Finance • 9 days ago

Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 9 days ago

Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs

[Artificial Intelligence helping improve human life and health digital concept] Vertigo3d/E+ via Getty Images * Esperion Therapeutics (NASDAQ:ESPR [https://seekingalpha.com/symbol/ESPR]) announced it has reached a settlement with Dr. Re... Full story

Yahoo Finance • 18 days ago

Oritain expands traceability offer to leather

Oritain’s proprietary methodology, already trusted across apparel, food, and agriculture, can now verify the geographic origin of leather from key producing countries across Europe, Africa and South America. Oritain says this capability i... Full story

Yahoo Finance • 23 days ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® (bempedoic acid) tab... Full story

Yahoo Finance • last month

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence – – Guideline Recognition of ‘Strike Early and Strike Strong’ Approach with Early Combination Lipid-Lowering Therap... Full story

Yahoo Finance • 2 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incenti... Full story

Yahoo Finance • 2 months ago

Esperion rises after revenue beat, Q1 profitability expectation

[display stock market charts] loveguli/E+ via Getty Images Esperion Therapeutics (NASDAQ:ESPR [https://seekingalpha.com/symbol/ESPR]) shares rose on Tuesday after the company reported second quarter revenue above estimates, and now expect... Full story

Yahoo Finance • 2 months ago

Esperion Therapeutics Inc (NASDAQ:ESPR) Beats Q2 2025 Revenue Forecasts and Reduces Losses Amid Strong Prescription Growth

ESPERION THERAPEUTICS INC (NASDAQ:ESPR [https://www.chartmill.com/stock/quote/ESPR/profile]) SURPASSES REVENUE ESTIMATES, NARROWS LOSSES IN Q2 2025 Esperion Therapeutics Inc (NASDAQ:ESPR [https://www.chartmill.com/stock/quote/ESPR/profile... Full story

Yahoo Finance • 2 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

– Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with T... Full story

Yahoo Finance • 2 months ago

Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors

We recently published These 10 Stocks are Winning Big. Esperion Therapeutics, Inc. (NASDAQ:ESPR) is one of the best-performing stocks on Monday. Esperion Therapeutics extended its winning streak to a fifth consecutive day on Monday, addin... Full story

Yahoo Finance • 3 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will... Full story

Yahoo Finance • 3 months ago

Esperion Appoints Craig Thompson to Board of Directors

ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent direc... Full story

Yahoo Finance • 6 months ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will... Full story

Yahoo Finance • 7 months ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y to $31.6 Million – – Q4 Retai... Full story

Yahoo Finance • 7 months ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLE... Full story

Yahoo Finance • 8 months ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Following the release, management will ho... Full story